Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Abivax SA Sponsored ADR ( (ABVX) ).
On July 22, 2025, Abivax SA announced positive results from its Phase 3 ABTECT-1 and ABTECT-2 8-week induction trials for obefazimod, a first-in-class oral miR-124 enhancer, in treating moderate to severely active ulcerative colitis. The trials demonstrated that the 50 mg once-daily dose of obefazimod met the FDA primary endpoint of clinical remission at Week 8, with significant placebo-adjusted remission rates and favorable tolerability. These results reinforce obefazimod’s potential as a transformative treatment option for ulcerative colitis, especially for patients with inadequate responses to previous therapies.
The most recent analyst rating on (ABVX) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Abivax SA Sponsored ADR stock, see the ABVX Stock Forecast page.
Spark’s Take on ABVX Stock
According to Spark, TipRanks’ AI Analyst, ABVX is a Neutral.
The overall stock score of 58 reflects significant financial challenges despite strong technical momentum. The company’s high operating losses and negative cash flows are major concerns, outweighing the bullish technical indicators. Valuation remains unattractive due to negative earnings.
To see Spark’s full report on ABVX stock, click here.
More about Abivax SA Sponsored ADR
Abivax SA is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
Average Trading Volume: 333,748
Technical Sentiment Signal: Hold
Current Market Cap: $639.4M
For an in-depth examination of ABVX stock, go to TipRanks’ Overview page.